Serotypes and clinical manifestations of invasive group B streptococcal infections in western Sweden 1998-2001.
暂无分享,去创建一个
P. Larsson | S. Berg | B. Trollfors | T. Ripa | E. Persson | E. Backhaus | E. Ek | G. Rådberg | B. Claesson | L. Jonsson | S. Johansson | Birger Trollfors | Elisabeth Ek | Peter Larsson | Elisabet Persson | Stefan Berg | B.E.B. Claesson
[1] B. Trollfors,et al. Invasive group B streptococcal infections in Sweden: incidence, predisposing factors and prognosis. , 2003, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[2] B. Trollfors,et al. Septicaemia and meningitis in neonates and during early infancy in the Göteborg area of Sweden , 2002, Acta paediatrica.
[3] N. Charland,et al. Protection from Group B Streptococcal Infection in Neonatal Mice by Maternal Immunization with Recombinant Sip Protein , 2002, Infection and Immunity.
[4] K. Bergh,et al. Typing of human isolates of Streptococcus agalactiae (group B streptococcus, GBS) strains from Zimbabwe. , 2002, Journal of medical microbiology.
[5] D. Kasper,et al. Conjugate vaccines against group B Streptococcus types IV and VII. , 2002, The Journal of infectious diseases.
[6] R. Collier,et al. Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen. , 2001, Vaccine.
[7] J. Troendle,et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study. , 2001, The Journal of infectious diseases.
[8] H. Davies,et al. Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation. , 2001, The Pediatric infectious disease journal.
[9] M. Farley. Group B streptococcal disease in nonpregnant adults. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] C. Adair,et al. Antibodies to capsular polysaccharides of group B Streptococcus in pregnant Canadian women: relationship to colonization status and infection in the neonate. , 2001, The Journal of infectious diseases.
[11] W. Ko,et al. Serotyping and Antimicrobial Susceptibility of Group B Streptococcus Over an Eight-Year Period in Southern Taiwan , 2001, European Journal of Clinical Microbiology and Infectious Diseases.
[12] L. Paoletti. Potency of clinical group B streptococcal conjugate vaccines. , 2001, Vaccine.
[13] M. Krohn,et al. Group B Streptococcal Colonization and Serotype‐Specific Immunity in Pregnant Women at Delivery , 2000, Obstetrics and gynecology.
[14] I. Charlebois,et al. Identification of Group B Streptococcal Sip Protein, Which Elicits Cross-Protective Immunity , 2000, Infection and Immunity.
[15] G. Tyrrell,et al. Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study--1996. Sentinel Health Unit Surveillance System Site Coordinators. , 2000, The Journal of infectious diseases.
[16] A. Schuchat,et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. , 2000, The New England journal of medicine.
[17] S. Berg,et al. Serotypes and clinical manifestations of group B streptococcal infections in western Sweden. , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[18] S. Kalliola,et al. Neonatal group B streptococcal disease in Finland: a ten-year nationwide study. , 1999, The Pediatric infectious disease journal.
[19] D. Kasper,et al. Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. , 1999, The Journal of infectious diseases.
[20] D. Kasper,et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. , 1999, The Journal of infectious diseases.
[21] A. Schuchat. Epidemiology of Group B Streptococcal Disease in the United States: Shifting Paradigms , 1998, Clinical Microbiology Reviews.
[22] A. Schuchat,et al. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. , 1998, The Journal of infectious diseases.
[23] P. Azimi,et al. Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection. , 1997, The Journal of infectious diseases.
[24] D. Kasper,et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1996, The Journal of clinical investigation.
[25] R. Edelman,et al. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults. , 1996, Vaccine.
[26] A. Schuchat,et al. Invasive group B streptococcal disease: the emergence of serotype V. , 1996, The Journal of infectious diseases.
[27] L. Bevanger,et al. A Streptococcus agalactiae R protein analysed by polyclonal and monoclonal antibodies , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[28] A. Schuchat,et al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. , 1993, The New England journal of medicine.
[29] G. Lindahl,et al. Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections , 1993, The Journal of experimental medicine.
[30] L. Madoff,et al. Neonatal group B streptococcal infection in Mallorca, Spain. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] L. Burman,et al. Novel coagglutination method for serotyping group B streptococci , 1992, Journal of clinical microbiology.
[32] L. Bevanger,et al. Characterization of the a antigen of the c proteins of group B streptococci (GBS) using a murine monoclonal antibody , 1992, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[33] A. Schuchat,et al. Invasive Group B Streptococcal Disease in Adults: A Population-Based Study in Metropolitan Atlanta , 1991 .
[34] B. Trollfors,et al. Incidence and Etiology of Neonatal Septicaemia and Meningitis in Western Sweden 1975‐1986 , 1990, Acta paediatrica Scandinavica.
[35] D. Kasper,et al. Immunization of Pregnant Women with a Polysaccharide Vaccine of Group B Streptococcus , 1988 .
[36] J. Motlová,et al. Worldwide distribution of two new serotypes of group B streptococci: type IV and provisional type V , 1985, Journal of clinical microbiology.
[37] M. Klegerman,et al. Type-specific capsular antigen is associated with virulence in late-onset group B Streptococcal type III disease , 1984, Infection and immunity.
[38] D. Kasper,et al. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. , 1977, The Journal of clinical investigation.
[39] D. Kasper,et al. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. , 1976, The New England journal of medicine.
[40] R. Krause,et al. NEW APPROACHES FOR THE LABORATORY RECOGNITION OF M TYPES OF GROUP A STREPTOCOCCI , 1971, The Journal of experimental medicine.
[41] R. Williams. Laboratory diagnosis of streptococcal infections. , 1958, Bulletin of the World Health Organization.
[42] G. Perlmann,et al. PREPARATION AND PROPERTIES OF A PROTEIN (R ANTIGEN) OCCURRING IN STREPTOCOCCI OF GROUP A, TYPE 28 AND IN CERTAIN STREPTOCOCCI OF OTHER SEROLOGICAL GROUPS , 1952, The Journal of experimental medicine.